News April 2017
On April 10, 2017 Enzyre obtained an exclusive license of the Radboudumc to a proprietary technology using chemiluminescence to detect enzymatic reactions using a light sensor chip and enzyme specific substrates. The technology was developed with funding of a PIDON grant by a consortium including NXP Semiconductors and Chiralix. The license agreement includes the option to purchase the patent protecting the technology. Enzyre will use the technology to develop a point-of-care biochip for blood coagulation able to measure multiple enzymatic reaction simultaneously. Together with the execution of the license agreement Radboudumc became a shareholder in Enzyre and invested an undisclosed amount in the development of the biochip.